Author： Ohkawa T. Goto S. Miki S. Sato A. Kuroda T. Iwatani K. Takeuchi M. Nakano M.
Publisher： Informa Healthcare
ISSN： 1366-5928
Source： Xenobiotica, Vol.28, Iss.9, 1998-09, pp. : 877-886
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
1. S-1153, a non-nucleoside agent that is under development in the USA as a new antiHIV agent, has potent antiviral activity based on the inhibition of reverse transcriptase. 2. S-1153wasincubatedwithratliver microsomes andNADPH,andsevenmetabolites were formed. The main metabolites were identified as the S -oxide, N -oxide and sulphone of S-1153. 3. Two other minor metabolites were assumed to be S-1153 hydroxylated on the isopropyl moiety. 4. Our findings confirmed the existence of at least three oxidative metabolic pathways of S-1153.
Related content
New Azt Conjugates as Potent Anti-HIV Agents
Nucleosides, Nucleotides & Nucleic Acids, Vol. 25, Iss. 1, 2006-01 ,pp. :
Access to resources
Recommend
By Nickmilder M. J. M. Latinne D. Verbeeck R. K. Janssens W. Svoboda D. Lhoest G. J. J.
Xenobiotica, Vol. 27, Iss. 9, 1997-09 ,pp. :
By Kwak Eun-Young Shim Won-Sik Chang Ji-Eun Chong Saeho Kim Dae-Duk Chung Suk-Jae Shim Chang-Koo
Xenobiotica, Vol. 42, Iss. 7, 2012-07 ,pp. :
By Ren J. Nichols C. Bird L. Chamberlain P. Weaver K. Short S. Stuart D.I. Stammers D.K.
Journal of Molecular Biology, Vol. 312, Iss. 4, 2001-09 ,pp. :